RYE, N.Y., Dec. 13, 2010 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has appointed Jennifer Katritos, CPA, as vice president of finance, the company announced. She joined Curemark in July, 2009 as director of finance. Katritos oversees Curemark's financial function, responsible for financial planning and reporting and risk analysis.
During her 20-year career, Katritos has held a variety of financial positions, primarily in the research-focused nonprofit sector. Prior to Curemark, she served as director of finance for the Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium. Previously, Katritos headed her own financial consulting practice with a focus on nonprofit and emerging businesses.
"We are extremely pleased about Jennifer's well-deserved and well-earned promotion," said Joan Fallon, Curemark founder and CEO. "She came to Curemark with a stellar financial background and extensive experience in the research space. She has exhibited strong leadership in the financial arena."
"It has been incredibly rewarding to utilize my financial expertise in a way that helps individuals in need. I am particularly thrilled to be working with Joan and the Curemark team," Katritos said. "I am inspired by their dedication to help children and families with the pervasive issue of autism."
Katritos began her career with Deloitte and Touche LLP in New York. She holds a BS in Accounting and Finance from the State University of New York at Oneonta.
Curemark is currently in Phase III clinical trials for CM-AT, an autism treatment which has received Fast Track status from the FDA.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
|SOURCE Curemark, LLC|
Copyright©2010 PR Newswire.
All rights reserved